Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 4, 2008, Pages 285-290

  Fischer, Juliana De Saldanha Da Gama ^a,d   Carvalho, Paulo Costa ^a   Neves Ferreira, Ana Gisele Da Costa ^b   Da Fonseca, Clovis Orlando ^c   Perales, Jonas ^b   Carvalho, Maria Da Gloria Da Costa ^a   Domont, Gilberto Barbosa ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^d Cidade Universitária   (Brazil)

Author keywords

Biomarker; Cancer; DIGE; Glioblastoma multiform; Perillyl alcohol; Proteomics

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; FIBRINOGEN; PERILLYL ALCOHOL; PLASMA PROTEIN;

ARTICLE; CANCER GROWTH; CANCER PATIENT; DIFFERENTIAL GEL ELECTROPHORESIS; DOWN REGULATION; GEL ELECTROPHORESIS; GLIOBLASTOMA; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; RECURRENT CANCER; UPREGULATION;

EID: 58649089102     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Clark SS, Zhong L, Filiault D, Perman, S, Ren Z, Gould M, Yang X. Anti-leukemia effect of perillyl alcohol in Ber/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion. Clin Cancer Res 9:4494-4504, 2003.
2. Clark SS, Perman SM, Sahin M B, Jenkins GJ, Elegbede JA. Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 16:213-222, 2002.
3. Burke YD, Ayoubi AS, Werner SR, McFarland BC, Heilman DK, Ruggeri BA, Crowell PL. Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res 22:3127-3134, 2002.
4. Yeruva L, Pierre KJ, Elegbede A, Wang RC, Carper SW. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett 257: 216-226, 2007.
5. Clark SS. Perillyl alcohol induces c-Myc-dependent apoptosis in Bcr/Abl-transformed leukemia cells. Oncology 70:13-18, 2006.
6. Chung BH, Lee H.Y, Lee JS, Young CY. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 236:222-228, 2006.
7. Yuri T, Danbara N, Tsujita-Kyutoku M, Kiyozuka Y, Senzaki H, Shikata N, Kanzaki H, Tsubura A. Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 84:251-260, 2004.
8. Loutrari H, Hatziapostolou M, Skouridou V, Papadimitriou E, Roussos C, Kolisis FN, Papapetropoulos A.. Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol.Exp Ther 311:568-575, 2004.
9. Teruszkin B, I ves de PS, Henriques SN, Curie CM, Gibaldi D, Bozza M, Orlando da FC, Da Gloria da Costa Carvalho. Effects of perillyl alcohol in glial C6 cell line in vitro and antimetastatic activity in chorioallantoic membrane model. Int J Mol Med 10:785-788, 2002.
10. Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas J P. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer 1. Int J Gastrointest Cancer 32:125-128, 2002.
11. Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 10:7583-7591, 2004.
12. Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol 85:464-468, 2002.
13. Da Fonseea CO, Landeiro JA, Clark SS, Quirico-Santos T, da Costa Carvalho MG, Gattass CR. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg.Neurol 65: Suppl 1, S1, 2006.
14. Da Fonseca CO, Schwartsmann G, Fischer JSG, Nagel J, Futuro D, Quirico-Santos T, Gattass CR. Preliminary results from a phase 1/11 study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol. 2008, (in press).
15. Jessani N, Niessen S, Wei BQ, Nicolau M, Humphrey M, Ji Y, Han W, Nob DY, Yates JR III, Jeffrey SS, Cravatt BF. A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods 2:691-697, 2005.
16. O'Farrell PH. High resolution two dimensional electrophoresis of proteins. J Biol Chem 25:4007-4021, 1975.
17. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 25:1327-1333, 2004.
18. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18:2071-2077, 1997.
19. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomic 3:36-44, 2003.
20. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382:669-678, 2005.
21. Echan LA, Tang HY, li-Khan N, Lee K, Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomic 5:3292-3303, 2005.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970.
23. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551-3567, 1999.
24. Rak J, Klement P, Yu J. Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek, 52: Suppl 1, 135-138, 2006.
25. Hua Y, Keep RF, Schallert T, Hoff JT, Xi G. A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. Acta Neurochir Suppl 86: 503-506, 2003.
26. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928, 1999.
27. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 138: 430-445, 2007.